Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
Purpose:
To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a corrected age of 3 years.
Methods:
A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for Type 1 ROP, from April 2011 to April 2014.
Comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ROP group | children with retinopathy of prematurity received either bevacizumab or ranibizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bevacizumab | Drug | intravitreal injection of bevacizumab |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| spherical equivalent | spherical power + half of cylinder power | at corrected age of 3 year-old |
| astigmatism | in cylinder power | at corrected age of 3 year-old |
| Measure | Description | Time Frame |
|---|---|---|
| axial length | axial length in mm | at corrected age of 3 year-old |
| cornea radius | cornea radius in mm | at corrected age of 3 year-old |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
infants who received intravitreal injection of ranibizumab or bevacizumab as the primary treatment
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25462435 | Result | Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015 Apr;35(4):667-74. doi: 10.1097/IAE.0000000000000380. | |
| 29713524 | Derived | Chen YC, Chen SN, Yang BC, Lee KH, Chuang CC, Cheng CY. Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age. J Ophthalmol. 2018 Mar 11;2018:4565216. doi: 10.1155/2018/4565216. eCollection 2018. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012178 | Retinopathy of Prematurity |
| D012030 | Refractive Errors |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D007235 | Infant, Premature, Diseases |
| D007232 | Infant, Newborn, Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| D000069579 | Ranibizumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ranibizumab | Drug | intravitreal injection of ranibizumab |
|
|
| anterior chamber depth | anterior chamber depth in mm | at corrected age of 3 year-old |
| lens thickness | lens thickness in mm | at corrected age of 3 year-old |
| D009358 |
| Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |